Keywords: Celgene, VentiRx Pharma, VTX-2337, Pomalidomide, TLR8 agonist, Multiple myeloma, USA, FDA
VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update
Article | 05 October 2012
VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
